Sugi Predict

Sugi Predict / Compounds / SCHEMBL4416867

SCHEMBL4416867

SCHEMBL4416867

CSc1ncc2cc(-c3cc(NC(=O)Nc4cc(C(C)(C)C)nn4C)c(F)cc3C)c(=O)n(C3CCCC3)c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 8/20 0.43
▸ RAF1 P04049 5/20 0.43
▸ MAPK14 Q16539 11/20 0.40
▸ MAPK13 O15264 5/20 0.40
▸ LMNA P02545 1/20 0.38
▸ KDR P35968 5/20 0.38
▸ KRAS P01116 4/20 0.38
▸ MAP2K2 P36507 3/20 0.38
▸ MAP2K1 Q02750 3/20 0.38
▸ ABL1 P00519 2/20 0.37
▸ MAPK12 P53778 3/20 0.35
▸ MAPK11 Q15759 3/20 0.35
▸ FYN P06241 1/20 0.34
▸ ARAF P10398 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ EPHA2 P29317 1/20 0.34
▸ CSK P41240 1/20 0.34
▸ MAPK8 P45983 1/20 0.34
▸ MAPK9 P45984 1/20 0.34
▸ IRAK1 P51617 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421388 0.89 BRAF (0.55) BRAFRAF1MAPK14MAPK13LMNA
SCHEMBL5061707 0.89 BRAF (0.46) BRAFRAF1MAPK14MAPK13LMNA
SCHEMBL4552758 0.87 BRAF (0.49) BRAFRAF1MAPK14MAPK13KDR
SCHEMBL5065248 0.81 BRAF (0.48) BRAFRAF1MAPK14MAPK13KDR
SCHEMBL4426093 0.80 MAPK14 (0.46) BRAFRAF1MAPK14MAPK13LMNA
SCHEMBL5061391 0.79 MAPK14 (0.51) BRAFRAF1MAPK14MAPK13MAPK12
SCHEMBL4424614 0.78 BRAF (0.49) BRAFRAF1MAPK14MAPK13LMNA
SCHEMBL4430966 0.78 BRAF (0.56) BRAFRAF1MAPK14MAPK13LMNA
SCHEMBL4279952 0.77 BRAF (0.61) BRAFRAF1MAPK14MAPK13KDR
SCHEMBL5066964 0.77 BRAF (0.70) BRAFRAF1MAPK14MAPK13LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885MAPK14 240/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885MAPK14 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.